| Renal Cell Carcinoma |
1 |
1 |
| Biologic Therapy |
0 |
0.9 |
| Targeted Cancer Therapy |
0 |
0.99 |
| Cancer |
0 |
0.54 |
| Thromboembolism |
0 |
0.51 |
| Antineoplastic Drug |
0 |
0.45 |
| Hypertension |
0 |
0.42 |
| Cerebrovascular Accident |
0 |
0.39 |
| Cytokines |
0 |
0.98 |
| Cardiovascular Risk Management |
0 |
0.38 |
| Tyrosine Kinase Inhibitor |
0 |
0.34 |
| Heart Failure (HF) |
0 |
0.27 |
| Atrial Fibrillation |
0 |
0.18 |
| Myocardial Infarction (MI) |
0 |
0.18 |
| Cardiovascular Imaging |
0 |
0.16 |
| Heart |
0 |
0.15 |
| Ischemic Stroke |
0 |
0.15 |
| Receptors |
0 |
0.15 |
| Vascular Endothelial Growth Factor |
0 |
0.15 |
| Interleukin-2 |
0 |
0.11 |
| Platelet-Derived Growth Factor |
0 |
0.11 |
| Coronary Flow Reserve |
0 |
0.08 |
| Hospital |
0 |
0.08 |
| Infarction |
0 |
0.08 |
| Interleukin |
0 |
0.08 |
| Platelet Count |
0 |
0.08 |
| Socioeconomics |
0 |
0.08 |
| Thrombosis |
0 |
0.08 |
| TOR Inhibitor |
0 |
0.08 |
| Tyrosine Kinase |
0 |
0.08 |
| Venous Thromboembolism (VTE) |
0 |
0.08 |
| Social Determinants of Health |
0 |
0.07 |